Verition Fund Management’s Aspire Biopharma Warrant ASBPW Stock Holding History

Verition Fund Management’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.92K	Hold	191,021	–	–	﹤0.01%	2047
2026 Q1	$3.17K	Sell	191,021 -241,736	-56%	-$4.93K	﹤0.01%	2189
2025 Q4	$7.14K	Hold	432,757	–	–	﹤0.01%	3446
2025 Q3	$12.9K	Hold	432,757	–	–	﹤0.01%	3701
2025 Q2	$19.3K	Hold	432,757	–	–	﹤0.01%	3565
2025 Q1	$29.3K	Hold	432,757	–	–	﹤0.01%	3226
2024 Q4	$20.6K	Hold	432,757	–	–	﹤0.01%	3166
2024 Q3	$18.3K	Hold	432,757	–	–	﹤0.01%	3078
2024 Q2	$13K	Hold	432,757	–	–	﹤0.01%	2883
2024 Q1	$13K	Hold	432,757	–	–	﹤0.01%	2685
2023 Q4	$26K	Hold	432,757	–	–	﹤0.01%	2203
2023 Q3	$21.6K	Hold	432,757	–	–	﹤0.01%	2219
2023 Q2	$21.7K	Hold	432,757	–	–	﹤0.01%	2069
2023 Q1	$18.1K	Hold	432,757	–	–	﹤0.01%	2017
2022 Q4	$34.6K	Hold	432,757	–	–	﹤0.01%	1903
2022 Q3	$48K	Sell	432,757 -7,964	-2%	-$1.16K	﹤0.01%	2695
2022 Q2	$4.4M	Buy	+440,721	New	+$95.9K	0.09%	305

Other funds holding ASBPW

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Verition Fund Management's ASBPW Position: Q2 2026 in Review

Verition Fund Management held its Aspire Biopharma Warrant (ASBPW) position steady in Q2 2026 at 191,021 shares worth $3.92K. The position accounts for ﹤0.01% of the portfolio, ranked #2047.

Verition Fund Management first reported a position in ASBPW in Q2 2022 and has held it in 17 quarters since. The position peaked at $4.4M in Q2 2022. 27 funds tracked by Wall St. Rank hold ASBPW as of Q2 2026.

Verition Fund Management held 191,021 shares of Aspire Biopharma Warrant worth $3.92K as of Q2 2026.
Verition Fund Management left its Aspire Biopharma Warrant share count unchanged in Q2 2026.
Aspire Biopharma Warrant made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #2047 holding.
Verition Fund Management first reported a position in Aspire Biopharma Warrant in Q2 2022 and has held it in 17 quarters since.
Verition Fund Management's Aspire Biopharma Warrant position peaked at $4.4M in Q2 2022.
27 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.